In addition, the SOF-based regimens group showed a higher percentage of decliners (76.1%, 38/46 patients) than the PR-based regimens group, which had only 58.8% (20/34) decliners, at the end of treatment, suggesting that the SOF-based treatments more efficiently reduced liver fibrosis than the PR treatment regimens immediately after treatment; in addition, alterations of CHI3L1 content might serve as the sensitive marker to monitor liver fibrosis changes within a short term in a noninvasive way (measured in weeks rather than in months). This evidence concerns the gene CHI3L1 and Hepatic fibrosis.